ClinicalTrials.gg
Active, not recruitingNCT07632976Updated Jun 8, 2026

A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis

A Phase 1 interventional study of EA5 and EA5 in Antiphospholipid Syndrome (APS) and Thrombosis, sponsored by Shanghai Lanyi Therapeutics Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Shanghai Lanyi Therapeutics Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Antiphospholipid Syndrome with a site in China — 20 open to participants now, 21 under way, none of them phase 3. Antiphospholipid Syndrome · China.

Planned enrollment
13th of 22
12 · median 15
Started
2026
with 2 others
Phase 1
9 of 25
8 open now
Primary completion
2027-09
later than 17 of 20 live
Registered
25th of 25
by date

Among the 25 studies in Antiphospholipid Syndrome with a site in China, this one is the 13th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 in phase 1, reaches primary completion later than 17 of the 20 other live ones, and was the 25th registered.

Antiphospholipid Syndrome

121 studies on the registry are indexed under Antiphospholipid Syndrome; 52 are open to participants now.

Browse Antiphospholipid Syndrome studies →

Open to participants now

20 of the 25 studies in Antiphospholipid Syndrome with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 38 Antiphospholipid Syndrome studies recruiting now, 14 (37%) set no upper age limit and 19 (50%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Antiphospholipid Syndrome with a site in China, or all of them as a file.
02

Study summary

This is a Phase I, open-label, dose escalation, multicenter study to evaluate the safety, tolerability, preliminary efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) of EA5 injection in adult participants with Antiphospholipid Syndrome (APS) and recurrent thrombosis who are receiving standard-of-care antithrombotic therapy. Approximately 12 participants will be enrolled. The whole study treatment cycle was 24 weeks. Administration of low-dose EA5: First, administer the loading dose regimen intravenously, then maintain administration subcutaneously every 2 weeks(Q2W). Administration of high-dose EA5: First, administer the loading dose regimen intravenously, then maintain administration subcutaneously every 2 weeks(Q2W).The primary objective is to assess safety and tolerability. Secondary objectives include evaluation of preliminary efficacy, immunogenicity, PK, PD (complement inhibition), and APS-related biomarker changes.

03

Conditions studied

  • Antiphospholipid Syndrome (APS)
  • Thrombosis

Keywords

  • EA5
  • Antiphospholipid Syndrome(APS),
  • Recurrent Thrombosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be ≥18 years of age at the time of signing the Form (ICF).
  2. Participants diagnosed with Antiphospholipid Syndrome (APS) according to the 2023 EULAR/ACR classification criteria, with at least two of the three antiphospholipid antibodies positive: anticardiolipin antibody (aCL), anti-β2-glycoprotein I antibody (anti-β2GPI), and lupus anticoagulant (LA).
  3. Experienced ≥2 thrombotic events within the past 5 years under antithrombotic prophylactic therapy, confirmed by objective imaging.
  4. Stable antithrombotic treatment regimen for at least 6 months prior to screening (dose adjustment of warfarin to achieve a stable is permitted).
  5. Vaccination against Neisseria meningitidis (MPV-ACYW) within \<3 years prior to initiation of study treatment; OR if not previously vaccinated, receipt of the meningococcal vaccine (MPV-ACYW) at least 14 days prior to the first dose of the product. If the vaccine is administered within 14 days before dosing, antibiotic prophylaxis must be provided until 2 weeks post-vaccination.
  6. Vaccination against Streptococcus pneumoniae according to national vaccination recommendations (e.g., Advisory Committee on Immunization Practices [ACIP] guidelines). OR if not previously vaccinated, receipt of the pneumococcal vaccine at least 14 days prior to the first dose of the investigational product. If the vaccine is administered within 14 days before dosing, antibiotic prophylaxis must be provided until 2 weeks post-vaccination.
  7. Use of by men and women should be consistent with local regulations regarding contraceptive methods for clinical trial participants.

(1)Male Participants: Male participants must agree to use effective contraception during the treatment period and for at least 6 months after the last dose of the study intervention, and to refrain from donating sperm during this time.

(2)Female Participants: Non-pregnant, non-lactating female participants are eligible to participate if they meet at least one of the following conditions: use of an effective or acceptable contraceptive method during the treatment period and for at least 6 months after the last dose of the study drug.

Capable of understanding the study procedures and methods, willing to sign the ICF, and able to strictly adhere to the clinical study protocol to complete the study.

Exclusion criteria

Exclusion Criteria:

  1. History of within 5 years prior to screening and before administration (except for localized skin basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ that have undergone curative local treatment with no evidence of in the past 3 years).
  2. Thrombosis with other definite etiologies, such as malignancy, hereditary thrombophilia, thrombotic microangiopathy, etc.
  3. History of catastrophic antiphospholipid syndrome (i.e., progressive thrombosis in multiple [3 or more] organs occurring within 1 week, involving critical organs such as the brain, kidneys, liver, or heart leading to failure, with pathological confirmation of small vessel thrombosis).
  4. Presence of active bleeding or high risk of bleeding, such as gastrointestinal bleeding, intracranial bleeding, respiratory tract bleeding, coagulation disorders, etc.
  5. History of major surgery within 1 month prior to screening or requiring major elective surgery during the trial period.
  6. History of immunodeficiency, including a positive test for (HIV) antibody, or having other acquired or congenital immunodeficiency diseases.
  7. Comorbid with systemic diseases (e.g., systemic lupus erythematosus, systemic sclerosis, etc.).
  8. Unresolved meningococcal infection.
  9. Positive for virus (HCV) antibody at screening (except for those with a negative HCV RNA result), positive for human immunodeficiency virus (HIV) antibody, positive for anti-Treponema pallidumantibody (TP-Ab) (except for those with a negative RPR or TRUST test), OR positive for virus (HBV) surface antigen (HBsAg) (except for those with an HBV DNA level ≤ 1000 IU/mL).
  10. Presence of active infection requiring systemic therapy within 4 weeks prior to the first use of the product (including herpes zoster, active tuberculosis, active Treponema palliduminfection, and fungal infections requiring systemic therapy).
  11. Participants with severe hepatic or renal impairment: (ALT) or aspartate aminotransferase (AST) ≥ 3 times the (ULN); total ≥ 2 times ULN; serum creatinine ≥ 2.5 times ULN, OR calculated ≤ 30 mL/min according to the Cockcroft-Gault formula.
  12. Receipt of other interventional therapy or participation in another clinical study within 30 days prior to the first use of the investigational product or within 5 half-lives of this investigational product (whichever is longer).
  13. Prior use of complement C3 or C5 targeted therapy.
  14. History of allergy to any component of EA5, including to human, humanized, or murine monoclonal antibodies, or known hypersensitivity to any ingredient of the product.
  15. Any disease that, in the opinion of the investigator or sponsor, may increase participant risk or confound study outcomes. Including, but not limited to, significant circulatory, respiratory, urinary, endocrine system diseases, etc.
  16. Female participants who are pregnant or breastfeeding.
  17. Any other condition for which the investigator considers the participant unsuitable to enter this clinical study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Queue 1: Administration of low-dose EA5 First, administer the loading dose regimen intravenously, then maintain administration subcutaneously every 2 weeks(Q2W).

    Biological: EA5

  • Experimental
    Cohort 2

    Queue 2: Administration of high-dose EA5 First, administer the loading dose regimen intravenously, then maintain administration subcutaneously every 2 weeks(Q2W).

    Biological: EA5

Interventions

  • BiologicalEA5

    Administer the loading dose regimen intravenously, then maintain administration subcutaneously

  • BiologicalEA5

    Administer the loading dose regimen intravenously, then maintain administration subcutaneously

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    TEAEs were defined as AEs that occurred on or after the date and time of study drug administration, or those that first occurred before dosing but worsened in frequency or severity after study drug administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Baseline up to Week28

Secondary outcomes

  1. Number of participants with adjudicated thrombotic events during the treatment period (including venous, arterial, and small-vessel thrombotic events)

    Time frame: Baseline up to Week28

  2. Number of adjudicated thrombotic events per participant

    Time frame: Baseline up to Week28

  3. Change in annualized thrombosis event rate compared to baseline (the 5-year period prior to treatment)

    Time frame: Baseline up to Week28

  4. Change in platelet count from baseline at each visit

    Time frame: Baseline up to Week28

  5. Situations requiring adjustment of antithrombotic treatment regimen during the treatment period

    Time frame: Baseline up to Week28

  6. Change in levels of sC5b-9 before and after dosing

    Time frame: Baseline up to Week28

  7. Change in levels of free C5 before and after dosing

    Time frame: Baseline up to Week28

  8. Incidence of anti-drug antibodies (ADA) against the humanized monoclonal antibody EA5

    Time frame: Baseline up to Week28

  9. Maximum Observed Serum Concentration (Cmax) of EA5

    Blood samples were collected for analysis of Cmax

    Time frame: Baseline up to Week28

  10. Time To Maximum Observed Serum Concentration (Tmax) of EA5

    Blood samples were collected for analysis of Tmax

    Time frame: Baseline up to Week 28

  11. Area Under The Serum Concentration Versus Time Curve From Time Zero To The Time of The Last Quantifiable Concentration (AUC0-t) of EA5

    Blood samples were collected for analysis of AUC0-t

    Time frame: Baseline up to Week 28

  12. Terminal Elimination Rate Constant (λz) of Serum EA5

    Blood samples were collected for analysis of λz

    Time frame: Baseline up to Week 28

  13. Terminal Elimination Half-life (t½) of Serum EA5

    Blood samples were collected for analysis of t½

    Time frame: Baseline up to Week 28

  14. Total Clearance (CL) of EA5

    Blood samples were collected for analysis of CL

    Time frame: Baseline up to Week 28

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 8, 2026
StartActual
May 25, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07632976
Lead sponsor
Shanghai Lanyi Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Jun 8, 2026
Start date
May 25, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EA5

Start the discussion